Top Markets
Coin of the day
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd

688336
Peringkat dalam Saham #3341
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd functions as a... Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd functions as a biopharmaceutical enterprise operating in China. This company is thoroughly engaged in the full lifecycle of antibody-based medicines, from their initial research and development to their production and subsequent market introduction. Its current portfolio includes YISAIPU, a tumor necrosis factor inhibitor utilized for treating rheumatic ailments; Xenopax, a recombinant humanized anti-CD25 monoclonal antibody delivered via injection; and Cipterbin, an anti-HER2 monoclonal antibody. Furthermore, the organization is actively progressing novel treatments designed for autoimmune disorders, various cancers, and other health issues. Established in 2002, its main offices are situated in Shanghai, China.
Harga Saham
$6.27
Kapitalisasi Pasar
$5.62B
Perubahan (1 hari)
-0.46%
Perubahan (1 tahun)
26.35%
Negara
CN
Perdagangan Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (688336)

Kategori

Jumlah saham beredar untuk Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (688336)
Jumlah saham beredar per August 2026: 0
Menurut laporan keuangan terbaru dan harga saham Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, jumlah saham beredar saat ini adalah 0. Pada akhir August 2026, perusahaan memiliki 0 saham beredar. Jumlah saham beredar biasanya dipengaruhi oleh pemecahan saham dan pembelian kembali saham.
Riwayat saham beredar untuk Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (688336) dari 2026 hingga 2026
Saham beredar pada akhir setiap tahun
Tahun Saham Beredar Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Saham beredar untuk perusahaan serupa atau pesaing
Perusahaan Saham Beredar Perbedaan Negara
253.90M -
US
62.19M -
NL
396.00M -
US
478.91M -
AU
- -
CH